Conclusion
Though rare, a child with XP requires to be investigated for acute leukaemia on development of bicytopenia. Tolerance to ALL chemotherapy was good in our XP paediatric patient except for the transient derangement of liver function tests, Pseudomonas sepsis and oral mucositis.
References:
1. Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis. 2011;6:70-70.
2. Pintens S, Pierret L, Keymolen K, Gutermuth J, De Raeve L. Xeroderma pigmentosum and leukaemia in two sisters. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016;30(10):e42-e43.
3. Oetjen KA, Levoska MA, Tamura D, et al. Predisposition to hematologic malignancies in patients with xeroderma pigmentosum. Haematologica. 2020;105(4):e144-e146.
4. Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W. Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects. Acta haematologica. 2013;129(2):121-125.
5. DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol. 2012;132(3 Pt 2):785-796.
6. ElMahgoub IR, Gouda HM, Samra MA, Shaheen IA, ElMaraashly AH. Polymorphisms of xeroderma pigmentosum genes (XPC, XPD, and XPG) and susceptibility to acute leukemia among a sample of Egyptian patients. Journal of Hematopathology. 2017;10(1):3-7.
7. Sarasin A, Quentin S, Droin N, et al. Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. Blood. 2019;133(25):2718-2724.
8. Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4):424-432.
9. Schaffer JV, Orlow SJ. Radiation therapy for high-risk squamous cell carcinomas in patients with xeroderma pigmentosum: report of two cases and review of the literature. Dermatology (Basel, Switzerland). 2011;223(2):97-103.
10. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer research. 2002;62(17):4899-4902.
11. Sumiyoshi M, Soda H, Sadanaga N, et al. Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum. Internal medicine (Tokyo, Japan). 2017;56(8):979-982.